Wednesday, 01 April, 2020

Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based AntibodyTherapy for the Treatment of Covid-19

CeNS spin-off active against Covid-19

Neurimmune AG and CeNS spin-off Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19.The collaboration brings together Neurimmune's expertise in developing human antibodies based on high-throughput immunoglobulin sequence analyses from Covid-19 patients who have recovered from the disease with Ethris' proprietary and unique pulmonarySNIM®RNA therapeutics platform. Both companies will work together to rapidly develop an immunotherapy designed toproduce therapeutic antibodies directly in the lungs of affected patients.

Ethris website